Systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease: Impact of pulmonary arterial hypertension therapies

Arthritis and Rheumatism

Volumn 63, Issue 8, 2011, Pages 2456-2464

  Le Pavec, Jérôme ^a,b,c,d   Girgis, Reda E ^a   Lechtzin, Noah ^a   Mathai, Stephen C ^a   Launay, David ^b,c,d,e   Hummers, Laura K ^a   Zaiman, Ari ^a   Sitbon, Olivier ^b,c,e   Simonneau, Gérald ^b,c,e   Humbert, Marc ^b,c,e   Hassoun, Paul M ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HÔPITAL ANTOINE BÉCLÈRE   (France)

^c CENTRE CHIRURGICAL MARIE LANNELONGUE   (France)

^d LILLE UNIVERSITY HOSPITAL   (France)

^e UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; DIURETIC AGENT; ENDOTHELIN RECEPTOR ANTAGONIST; OXYGEN; PHOSPHODIESTERASE V INHIBITOR; PROSTACYCLIN DERIVATIVE; PROSTANOID;

ADULT; AGED; ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEART CATHETERIZATION; HEART FAILURE; HEMODYNAMIC PARAMETERS; HUMAN; HYPOXEMIA; INTERSTITIAL LUNG DISEASE; ISCHEMIA; KAPLAN MEIER METHOD; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MESENTERY ISCHEMIA; NEOPLASM; OXYGENATION; PATIENT REFERRAL; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PULMONARY HYPERTENSION; RESPIRATORY FAILURE; RETROSPECTIVE STUDY; SURVIVAL; SYSTEMIC SCLEROSIS; WORLD HEALTH ORGANIZATION;

EID: 79961114967     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.30423     Document Type: Article

References (43)

1. Jimenez SA, Derk CT,. Following the molecular pathways toward an understanding of the pathogenesis of systemic sclerosis. Ann Intern Med 2004; 140: 37-50. (Pubitemid 38055920)
2. Steen VD, Medsger TA,. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 2007; 66: 940-4. (Pubitemid 46999798)
3. Humbert M, Sitbon O, Simonneau G,. Treatment of pulmonary arterial hypertension. N Engl J Med 2004; 351: 1425-36.
4. Le Pavec J, Humbert M, Mouthon L, Hassoun PM,. Systemic sclerosis-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 2010; 181: 1285-93.
5. Chang B, Wigley FM, White B, Wise RA,. Scleroderma patients with combined pulmonary hypertension and interstitial lung disease. J Rheumatol 2003; 30: 2398-405. (Pubitemid 37413900)
6. Mathai SC, Hummers LK, Champion HC, Wigley FM, Zaiman A, Hassoun PM, et al. Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease. Arthritis Rheum 2009; 60: 569-77.
7. Condliffe R, Kiely DG, Peacock AJ, Corris PA, Gibbs JS, Vrapi F, et al. Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med 2009; 179: 151-7.
8. Altman RD, Medsger TA Jr, Bloch DA, Michel BA,. Predictors of survival in systemic sclerosis (scleroderma). Arthritis Rheum 1991; 34: 403-13.
9. Trad S, Amoura Z, Beigelman C, Haroche J, Costedoat N, Du Boutin TH, et al. Pulmonary arterial hypertension is a major mortality factor in diffuse systemic sclerosis, independent of interstitial lung disease. Arthritis Rheum 2006; 54: 184-91. (Pubitemid 43122201)
10. Girgis RE, Mathai SC,. Pulmonary hypertension associated with chronic respiratory disease. Clin Chest Med 2007; 28: 219-32. (Pubitemid 46335933)
11. Launay D, Sitbon O, Le Pavec J, Savale L, Tcherakian C, Yaici A, et al. Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil. Rheumatology (Oxford) 2010; 49: 490-500.
12. Williams MH, Das C, Handler CE, Akram MR, Davar J, Denton CP, et al. Systemic sclerosis associated pulmonary hypertension: improved survival in the current era. Heart 2006; 92: 926-32. (Pubitemid 43974055)
13. LeRoy EC, Medsger TA Jr., Criteria for the classification of early systemic sclerosis. J Rheumatol 2001; 28: 1573-6.
14. Guyatt GH, Sullivan MJ, Thompson PJ, Fallen EL, Pugsley SO, Taylor D, et al. The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure. Can Med Assoc J 1985; 132: 919-23.
15. Simonneau G, Robbins IM, Beghetti M, Channick RN, Delcroix M, Denton CP, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009; 54: S43-54.
16. Crapo RO, Morris AH, Gardner RM,. Reference spirometric values using techniques and equipment that meet ATS recommendations. Am Rev Respir Dis 1981; 123: 659-64. (Pubitemid 11117589)
17. Goh NS, Desai SR, Veeraraghavan S, Hansell DM, Copley SJ, Maher TM, et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med 2008; 177: 1248-54. (Pubitemid 351860934)
18. Crapo RO, Morris AH,. Standardized single breath normal values for carbon monoxide diffusing capacity. Am Rev Respir Dis 1981; 123: 185-9. (Pubitemid 11146393)
19. Crapo RO, Morris AH, Clayton PD, Nixon CR,. Lung volumes in healthy nonsmoking adults. Bull Eur Physiopathol Respir 1982; 18: 419-25. (Pubitemid 12117075)
20. Montani D, Price LC, Dorfmuller P, Achouh L, Jais X, Yaici A, et al. Pulmonary veno-occlusive disease. Eur Respir J 2009; 33: 189-200.
21. Weitzenblum E, Chaouat A, Canuet M, Kessler R,. Pulmonary hypertension in chronic obstructive pulmonary disease and interstitial lung diseases. Semin Respir Crit Care Med 2009; 30: 458-70.
22. Steen V, Medsger TA Jr., Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum 2003; 48: 516-22. (Pubitemid 36278021)
23. Hachulla E, Launay D, Mouthon L, Sitbon O, Berezne A, Guillevin L, et al. Is pulmonary arterial hypertension really a late complication of systemic sclerosis? Chest 2009; 136: 1211-9.
24. Steen V,. Predictors of end stage lung disease in systemic sclerosis. Ann Rheum Dis 2003; 62: 97-9. (Pubitemid 36135382)
25. Fisher MR, Mathai SC, Champion HC, Girgis RE, Housten-Harris T, Hummers L, et al. Clinical differences between idiopathic and scleroderma-related pulmonary hypertension. Arthritis Rheum 2006; 54: 3043-50. (Pubitemid 44497786)
26. Kawut SM, Taichman DB, Archer-Chicko CL, Palevsky HI, Kimmel SE,. Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. Chest 2003; 123: 344-50. (Pubitemid 36269414)
27. Simonneau G, Escourrou P, Duroux P, Lockhart A,. Inhibition of hypoxic pulmonary vasoconstriction by nifedipine. N Engl J Med 1981; 304: 1582-5. (Pubitemid 11122507)
28. Campo A, Mathai SC, Le Pavec J, Zaiman AL, Hummers LK, Boyce D, et al. Hemodynamic predictors of survival in scleroderma-related pulmonary arterial hypertension. Am J Respir Crit Care Med 2010; 182: 252-60.
29. Badesch DB, Hill NS, Burgess G, Rubin LJ, Barst RJ, Galie N, et al. Sildenafil for pulmonary arterial hypertension associated with connective tissue disease. J Rheumatol 2007; 34: 2417-22. (Pubitemid 350230665)
30. Badesch DB, Tapson VF, McGoon MD, Brundage BH, Rubin LJ, Wigley FM, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease: a randomized, controlled trial. Ann Intern Med 2000; 132: 425-34. (Pubitemid 30149039)
31. Girgis RE, Frost AE, Hill NS, Horn EM, Langleben D, McLaughlin VV, et al. Selective endothelin A receptor antagonism with sitaxsentan for pulmonary arterial hypertension associated with connective tissue disease. Ann Rheum Dis 2007; 66: 1467-72. (Pubitemid 350032654)
32. Olschewski H, Ghofrani HA, Walmrath D, Schermuly R, Temmesfeld-Wollbruck B, Grimminger F, et al. Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis. Am J Respir Crit Care Med 1999; 160: 600-7. (Pubitemid 29380679)
33. Denton CP, Humbert M, Rubin L, Black CM,. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions. Ann Rheum Dis 2006; 65: 1336-40. (Pubitemid 44620443)
34. Girgis RE, Mathai SC, Krishnan JA, Wigley FM, Hassoun PM,. Long-term outcome of bosentan treatment in idiopathic pulmonary arterial hypertension and pulmonary arterial hypertension associated with the scleroderma spectrum of diseases. J Heart Lung Transplant 2005; 24: 1626-31. (Pubitemid 41396463)
35. Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006; 354: 2655-66.
36. Ghofrani HA, Wiedemann R, Rose F, Schermuly RT, Olschewski H, Weissmann N, et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet 2002; 360: 895-900. (Pubitemid 35283832)
37. Olschewski H, Simonneau G, Galie N, Higenbottam T, Naeije R, Rubin LJ, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002; 347: 322-9. (Pubitemid 34815354)
38. Seibold JR, Denton CP, Furst DE, Guillevin L, Rubin LJ, Wells A, et al. Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosis [published erratum appears in Arthritis Rheum 2010;62:3005]. Arthritis Rheum 2010; 62: 2101-8.
39. Avouac J, Kowal-Bielecka O, Landewe R, Chwiesko S, Miniati I, Czirjak L, et al and EUSTAR coauthors. European League Against Rheumatism (EULAR) Scleroderma Trial and Research group (EUSTAR) recommendations for the treatment of systemic sclerosis: methods of elaboration and results of systematic literature research. Ann Rheum Dis 2009; 68: 629-34.
40. Schachna L, Medsger TA Jr, Dauber JH, Wigley FM, Braunstein NA, White B, et al. Lung transplantation in scleroderma compared with idiopathic pulmonary fibrosis and idiopathic pulmonary arterial hypertension. Arthritis Rheum 2006; 54: 3954-61. (Pubitemid 44955899)
41. Saggar R, Khanna D, Furst DE, Belperio JA, Park GS, Weigt SS, et al. Systemic sclerosis and bilateral lung transplantation: a single center experience. Eur Respir J 2010; 36: 893-900.
42. Shitrit D, Amital A, Peled N, Raviv Y, Medalion B, Saute M, et al. Lung transplantation in patients with scleroderma: case series, review of the literature, and criteria for transplantation. Clin Transplant 2009; 23: 178-83.
43. Benza RL, Miller DP, Gomberg-Maitland M, Frantz RP, Foreman AJ, Coffey CS, et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation 2010; 122: 164-72.